Bill Poland
Overview
Explore the profile of Bill Poland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Poland B, Green M, Wong S, Slatter J
Xenobiotica
. 2022 Sep;
52(6):555-566.
PMID: 36052821
Navtemadlin is a potent, selective, orally available inhibitor of murine double minute 2 that restores p53 activity to induce apoptosis in wild-type malignancies. Using richly sampled pharmacokinetic (PK) and pharmacodynamic...
2.
Jiang X, Wada R, Poland B, Kleijn H, Fan B, Liu G, et al.
Clin Transl Sci
. 2021 Jan;
14(3):942-953.
PMID: 33493392
Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and...
3.
Taylor A, Lee D, Allard M, Poland B, Slatter J
Clin Pharmacol Drug Dev
. 2021 Jan;
10(8):918-926.
PMID: 33460527
Cardiac safety and plasma concentration-QTc interval analyses were completed using data from 2 phase 1 studies of the selective mouse double minute chromosome 2 antagonist, KRT-232, in patients with solid...
4.
Lee P, Abrams D, Bachand A, Baker G, Black R, Camacho O, et al.
Nicotine Tob Res
. 2020 Jun;
23(3):426-437.
PMID: 32496514
Introduction: Various approaches have been used to estimate the population health impact of introducing a Modified Risk Tobacco Product (MRTP). Aims And Methods: We aimed to compare and contrast aspects...
5.
Zhu R, Poland B, Wada R, Liu Q, Musib L, Maslyar D, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Feb;
8(4):240-248.
PMID: 30762302
The aims of this work were to characterize ipatasertib exposure-response (E-R) relationships in a phase II study and to quantitatively assess benefit-risk using a clinical utility index approach to support...
6.
Poland B, Teischinger F
Nicotine Tob Res
. 2017 Apr;
19(11):1277-1283.
PMID: 28371856
Introduction: As suggested by the Food and Drug Administration (FDA) Modified Risk Tobacco Product (MRTP) Applications Draft Guidance, we developed a statistical model based on public data to explore the...
7.
Garrett M, Poland B, Brennan M, Hee B, Pithavala Y, Amantea M
Br J Clin Pharmacol
. 2013 Jul;
77(3):480-92.
PMID: 23834452
Aims: Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma....
8.
Rini B, Garrett M, Poland B, Dutcher J, Rixe O, Wilding G, et al.
J Clin Pharmacol
. 2013 Apr;
53(5):491-504.
PMID: 23553560
Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic...
9.
Houk B, Bello C, Poland B, Rosen L, Demetri G, Motzer R
Cancer Chemother Pharmacol
. 2009 Dec;
66(2):357-71.
PMID: 19967539
Purpose: In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal...
10.
Rosario M, Poland B, Sullivan J, Westby M, van der Ryst E
J Acquir Immune Defic Syndr
. 2006 Apr;
42(2):183-91.
PMID: 16639345
Objectives: To use a viral dynamics model to compare the effectiveness of in vivo viral inhibition of several doses of maraviroc (MVC;UK-427,857) and to use a modeling approach to support...